Latest Pharma Insights
Siemens’ 30% Healthineers Spin-Off Signals $23.2 Billion Unwind As Analysts Warn Of Pressure
CEO Bernard Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
CEO Bernard Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
Hemp’s Preclusion For Use As Dietary Ingredient In US Continues Even With THC Concerns Resolved
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results
The Phase III portion of the Phase II/III RISE UP study in sickle cell disease met the hemoglobin response primary endpoint, but not the sickle cell pain crisis reduction co-primary endpoint nor a secondary endpoint on reducing fatigue.
Scrip - November 19, 2025
The Phase III portion of the Phase II/III RISE UP study in sickle cell disease met the hemoglobin response primary endpoint, but not the sickle cell pain crisis reduction co-primary endpoint nor a secondary endpoint on reducing fatigue.
Scrip - November 19, 2025
Alkermes Fires Back In Bidding War With Lundbeck Over Avadel
The drugmaker increased its offer to $21 per share – equal to Lundbeck’s counteroffer – with the same $1.50 CVR tied to Lumryz’s approval, which Avadel called superior.
Scrip - November 19, 2025
The drugmaker increased its offer to $21 per share – equal to Lundbeck’s counteroffer – with the same $1.50 CVR tied to Lumryz’s approval, which Avadel called superior.
Scrip - November 19, 2025
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.
Scrip - November 19, 2025
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.
Scrip - November 19, 2025
Jefferies 25: Pfizer Still Hungry For Anti-Obesity Deals After Metsera
Forced to spend more than it wanted on Metsera, Pfizer’s M&A coffers are now depleted but it is still interested in weight loss pills and immunology & inflammation assets.
Scrip - November 19, 2025
Forced to spend more than it wanted on Metsera, Pfizer’s M&A coffers are now depleted but it is still interested in weight loss pills and immunology & inflammation assets.
Scrip - November 19, 2025
Jefferies 25: Leo Ready To Leap Into More Deals
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Scrip - November 19, 2025
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Scrip - November 19, 2025
Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
Scrip - November 19, 2025
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
Scrip - November 19, 2025
Glenmark 3.0 In The Making, Invigorated By IGI-AbbVie Deal
Buoyed by the milestone AbbVie deal, Glenmark expects to “pay down” its debt and is also changing certain legacy practices as it seeks to ascend the value chain to become more of a branded company.
Scrip - November 19, 2025
Buoyed by the milestone AbbVie deal, Glenmark expects to “pay down” its debt and is also changing certain legacy practices as it seeks to ascend the value chain to become more of a branded company.
Scrip - November 19, 2025
Siemens’ 30% Healthineers Spin-Off Signals $23.2 Billion Unwind As Analysts Warn Of Pressure
CEO Bernard Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
CEO Bernard Montag said a reduced Siemens stake could make Healthineers attractive to new investors.
Medtech Insight - November 20, 2025
Hemp’s Preclusion For Use As Dietary Ingredient In US Continues Even With THC Concerns Resolved
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Regardless of THC level and even though the US hemp product marketplace is growing, FDA regulations prohibit the botanical’s use as a dietary ingredient or food additive because it’s been studied or approved for use as a drug in the US.
HBW Insight - November 20, 2025
Zydus Gears Up For Specialty Acquisitions, Gets gLynparza And Other Approvals
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline.
Generics Bulletin - November 19, 2025
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline.
Generics Bulletin - November 19, 2025
‘The Future Of Pharma Is Still Small-Molecule’ – Axplora Outlines API Investment Strategy
Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.
Generics Bulletin - November 19, 2025
Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.
Generics Bulletin - November 19, 2025
Formycon Maintains A Brave Face As Potential Missed Guidance Looms Over Q3 Results
Formycon continues preaching its confidence that it will meet the full-year guidance, despite facing a steep revenue void of €35.5m needed to meet the target.
Generics Bulletin - November 19, 2025
Formycon continues preaching its confidence that it will meet the full-year guidance, despite facing a steep revenue void of €35.5m needed to meet the target.
Generics Bulletin - November 19, 2025
ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
Deals In Depth: October 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
Podcast: Data-Driven Insights Reveal The Growth Engines Powering 2026 Life Sciences
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025